p16 cutoff in head and neck squamous cell carcinoma: correlation between tumor and patient characteristics and outcome.

Bolognesi C, Buschini A, Branchi E, Carboni P, Furlini M, Martino A, Monteverde M, Poli P, Rossi C.

Comet and micronucleus assays in zebra mussel cells for genotoxicity assessment of surface drinking water treated with three different disinfectants. Sci Total Environ. 2004 Oct 15.  IF 3.286

Bottero S, Cevasco A, Monteverde M, Pedemonte F, Bertolotti R, Viganò L, Mandich A, Massari A.

In vivo and in vitro exposures of carp and carp tissues to graded concentrations of endocrine disrupting chemicals. Ann N Y Acad Sci. 2005 Apr. IF 2.847

Puzzi C, Bottero S, Cevasco A, Massari A, Monteverde M, Pedemonte F, Bertolotti R, Viganò L, Mandich A.

Fish community characterization in two stretches upstream and downstream of the Lambro River confluence with the Po River. Ann N Y Acad Sci. 2005 Apr.  IF 2.847

Magni P, De Falco G, Falugi C, Franzoni M, Monteverde M, Perrone E, Sgro M, Bolognesi C.

Genotoxicity biomarkers and acetylcholinesterase activity in natural populations of Mytilus galloprovincialis along a pollution gradient in the Gulf of Oristano (Sardinia, western Mediterranean). Environ Pollut. 2006 Jul;142(1):65-72. Epub 2005 Nov 14. IF 3.746

Olga Zegarra-Moran, Martino Monteverde, Luis J.V. Galietta, Oscar Moran

Functional analysis of mutations in the putative binding site for CFTR potentiators: interaction between activation and inhibition. JBC 2007. IF 5.328

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol 2009. IF 2.261

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

“Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer”, International Journal of Oncology, 37: 1219-1228, 2010.  IF 5.673

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O’Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.

 Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal Clinical Investigation, 2010;120(8):2842-57. IF 15.387

Viganò L, Benfenati E, Bottero S, Cevasco A, Monteverde M, Mandich A.

“Endocrine modulation, inhibition of ovarian development and hepatic alterations in rainbow trout exposed to polluted river water.”, Environ Pollut. 2010 Dec; 158(12):3675-83. IF 3.426

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

“Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.”, Urol Oncol. 2011 Jul 25. IF 3.172

Lo Nigro C, Vivenza, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan P, Syed N, Roncarolli F, Shousha S, Purdie CA, Thompson A, Palmieri C, Crook T.

“High frequency of complex TP53 mutations in CNS metastases from breast cancer”, Br J Cancer 2011 Dec. IF 5.042

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

“Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis”. Cardiovasc Toxicol. 2012 Jun;12(2):135-42. IF 2.067

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C.

“MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck  cancer”. Oral Oncol. 2012 Jul;48(7):602-7. Epub 2012 Feb 21. IF 2.857

 Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T.

“NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity”. Br J Cancer. 2012 Apr 10;106(8):1446-52.  IF 5.082

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento  P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C,  Merlano M, Milano G.

“Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines”. Urol Oncol. 2012 May 17  IF 3.172

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.

“Methylation of the calcium canne regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas”. Br J Cancer. 2012 May 29.   IF 5.082

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

“NT5E CpG island methylation is a favourable breast cancer biomarker”. Br J Cancer. 2012 May 31.       IF 5.082

Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, Giurlanda F, Numico G, Russi E.

“Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer”. Oral Oncol. 2012 Jun          IF 2.857

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M; Syed N, Thompson A, Garrone O, Merlano M, Crook T, Lo Nigro C.

“Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse”, British Journal of Cancer, Br J Cancer. 2012 Jul 10. IF 5.082

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, Elguetakarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T.

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br J Cancer. 2012 Sep 6. IF 5.082

Lattanzio L, Tonissi F, Monteverde M, Merlano M, Lo Nigro C.

Regulation of SSTR2 and SSTR5 by the combined treatment docetaxel and somatostatin analogue octreotide in PC3 prostate cancer cells. Anticancer Drugs, 2012 Sep 16. IF 2.407

Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.

Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anticancer Drugs. 2013 Feb. IF 2.407

Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.

“Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma”. Int J Biol Markers. 2013 Aug 30:0. doi: 10.5301/jbm.5000041.  IF 1,592